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CLINICAL INVESTIGATION
Expression of transforming growth factor-/31 during diabetic
renal hypertrophy
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Department of Medicine, University of Toronto, Toronto, Ontario, Canada
Expression of transforming growth factor-fl during diabetic renal
hypertrophy. Experimental type I diabetes mellitus is characterized by an
early increase in kidney weight and glomerular volume, but changes in
gene expression accompanying diabetic renal growth have not been fully
elucidated. In the current study, total RNA was extracted from renal
cortex and isolated glomeruli of streptozotocin-induced diabetic rats 24
hours, 48 hours, 96 hours, one and two weeks after the onset of
hyperglycemia (blood glucose >15 mmol/liter), insulin-treated diabetic
rats (blood glucose <6.0 mmol/liter), and normal rats. RNA samples were
reverse transcribed (RT) and subjected to polymerase chain reaction
(PCR) amplication with specific 5' and 3' primers for rat transforming
growth factor (TGF-/31) and -actin. RT-PCR analysis revealed that
glomerular TGF-/31 mRNA levels increased relative to 13-actin as early as
24 hours after the onset of hyperglycemia, reaching a plateau after 96
hours that was sustained at one and two weeks. In cortical samples,
TGF-$1 mRNA levels increased less abruptly, reaching a peak one week
after the onset of hyperglycemia. Intensive insulin treatment to normalize
blood glucose levels attenuated the rise in glomerular and renal cortical
TGF-f 1 mRNA. Cryostat sections of rat kidneys were immunostained for
TGF-f31 utilizing a polyclonal anti-porcine TGF-131 antibody and semi-
quantitative scoring of TGF-/31 immunostaining revealed a twofold in-
crease in diabetic glomeruli after two weeks compared to normal glomer-
uli. Increased segmental immunostaining for TGF-f31 was also evident in
cortical tubules of diabetic rats. These studies establish that TGF-j31
expression in the kidney increases during the phase of rapid renal
hypertrophy in diabetic rats. Normalization of blood glucose levels with
insulin treatment attenuates the increase in TGF-$31 expression.
Experimental type I diabetes mellitus is characterized by an
early increase in kidney size, although the mechanism(s) under-
lying this response have not been completely elucidated. Studies
of streptozotocin-induced diabetic rats have shown that there is a
phase of rapid renal growth that follows the onset of hyperglyce-
mia so that both whole kidney weight and glomerular volume
increase. The increase in kidney size occurs predominantly by a
process of cell hypertrophy [1], although there is a component of
tubule cell hyperplasia. The early increase in glomerular volume is
accompanied by an increase in filtration surface area, a mecha-
nism that may account in part for the increase in glomerular
filtration rate [2]. During the early rapid phase of diabetic
glomerular hypertrophy there is a proportional increase in the
Received for publication August 20, 1993
and in revised form March 11, 1994
Accepted for publication March 14, 1994
© 1994 by the International Society of Nephrology
430
mesangium, but the later stage of type I diabetes mellitus is
characterized by progressive mesangial expansion, eventually
leading to a decrease in filtration surface area and a decrease in
glomerular filtration rate [3].
In vitro studies have shown that when mesangial [4] and
proximal tubule cells [5] are exposed to high glucose concentra-
tions, the cells increase production of the cytokine, transforming
growth factor-131 (TGF-/31). TGF-/31 is an important modulator
of cell growth [6]. It inhibits cell division in glomerular mesangial
[4, 7—10], epithelial, and endothelial cells [11]. Moreover, studies
by Dzau and coworkers have shown that angiotensin Il-induced
hypertrophy of vascular smooth cells is due to an autocrine effect
of TGF-f31 [12]. Recently, Choi and coworkers have shown that
mesangial cells hypertrophy when exposed to TGF-f31 in vitro [13].
Thus, an early increase in TGF-/31 expression in vivo could
mediate cellular responses during the early phase of renal and
glomerular hypertrophy that follows the onset of hyperglycemia.
A sustained increase in TGF-J31 expression after diabetic glomer-
ular hypertrophy is established, as has been demonstrated by
Yamamoto et al [14] and Nakamura et al [15], and would then link
changes in gene expression during hypertrophy to subsequent
glomerular injuty.
Accordingly, we sought to determine whether TGF-131 expres-
sion increased in glomeruli and renal cortical tissue of diabetic
rats during the early phase of rapid renal hypertrophy.
Methods
Animal model
Male Sprague-Dawley rats weighing 280 to 300 g received
streptozotocin, 60 mg/kg body weight, via a single tail vein
injection. A first group received no insulin treatment while a
second group received insulin twice daily (heat-treated ultralente
insulin, Novo Industri A/S, Copenhagen, Denmark) to normalize
blood glucose levels. Age-matched normal rats served as the
control group. Tail samples of blood were obtained beginning six
hours after administration of streptozotocin for determination of
blood glucose concentration with an Ames Accutest Glucometer.
After the onset of hyperglycemia, defined as blood glucose levels
greater than 15 mmol/liter, the blood glucose level was measured
daily in the untreated diabetic rats and twice daily in the diabetic
rats treated with insulin. Rats were excluded if their blood glucose
levels were below 15 mmol/liter. All of the animals had unlimited
access to chow (Purina Rat Chow) and water.
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Untreated diabetic rats were studied at 24, 48, and 96 hours,
and one and two weeks after the onset of hyperglycemia. Treated
diabetic rats were studied one and two weeks after the onset of
hyperglycemia. Two groups of age-matched normal rats served as
separate control groups. At each time point, the kidneys from five
rats were pooled for isolation of total RNA from glomeruli and
renal cortical tissue. For immunohistochemical analysis, kidneys
of three untreated diabetic rats were obtained two weeks after the
onset of hyperglycemia along with three age-matched normal rats.
Glomerular isolation
Rats were anesthetized with Brietal (50 mg/kg) intraperitone-
ally and the kidneys were rapidly removed. Perirenal fat was
trimmed, the capsule stripped off, and the cortex separated from
the medulla. The tissue was placed in ice-cold PBS buffer (pH 7.4)
and cut into 2 mm3 pieces. Approximately 1/10 of the tissue was
homogenized and used for cortical RNA analysis, and the remain-
der of the tissue was used for glomerular isolation by the
technique of differential sieving. This was performed by passing
the tissue through a 250 m sieve with a glass rod, collected onto
a 106 .tm sieve, and resuspended in ice-cold PBS before centrif-
ugation at 2000 g for 10 minutes at 4°C. After resuspending the
pellet in ice-cold PBS (pH 7.4), the suspension was drawn up into
a 10 cc syringe through a 20 gauge needle and discharged several
times before centrifugation at 2000 g for 10 minutes at 4°C. The
tissue pellet was resuspended, centrifuged and then resuspended
in ice-cold PBS (pH 7.4), then pushed through a 75 m sieve with
ice-cold buffer. After the glomeruli were collected on the 75 m
screen and resuspended in ice-cold PBS (pH 7.4), the purity of the
preparation was examined with a microscope. On average, there
were fewer than five tubular fragments per 100 glomeruli. These
glomeruli were then used for RNA isolation.
RNA isolation
Total RNA from both the glomerular and renal cortical tissue
was extracted by the single step method of Chomzynsky and
Sacchi [161. Two milliliters of a solution containing guandinium
isothiocyanate and 2-mercaptoethanol were added to the glomer-
ular suspension and vortexed; 0.2 ml of 2 M Na acetate, 2,0 ml of
phenol, and 0.4 ml of chloroform were then added, vortexed and
the solution was placed on ice for 15 minutes. An equal volume of
isopropanol was added to the aqueous phase and incubated at
— 20°C for 30 minutes. Total RNA was pelleted by centrifugation
at 8000 rpm for 20 minutes, resuspended in 300 1.d of a solution
containing guandinium isothiocyanate and 2-mercaptoethanol
and 300 d of isopropanol, and incubated at —20°C for 30
minutes. After centrifugation, the pellet was resuspended in 300
d of cold 70% ethanol, and the RNA stored in DEPC-treated
water at —70°C until used. After thawing, the purity and concen-
tration was determined by measuring the optical densities at 260
and 280 nm. The A260/A280 ranged from 1.75 to 1.95. Twenty
micrograms of total RNA were separated by electrophoresis on
1% agarose gels containing ethidium bromide, transferred to a
nylon filter (Hybond N), and cross-linked by UV illumination.
RT-PCR
One microgram of total RNA (10 p1 vol) was combined with 10
U RNAsin and 300 pmol of random hexamers. The mixture was
heated to 65°C for five minutes and cooled on ice. After the
addition of 20 U of Moloney Murine Leukemia Virus reverse
transcriptase (M-MLV-RT), 10 U of RNAsin, and 4 ,td of 5 X RT
buffer so that the final volume was 20 1.d, the reaction mixture was
incubated at 42°C for two hours. The reaction was stopped by
heating at 95°C for five minutes. The sample was then diluted to
100 p1 with deionized water and stored at —70°C prior to
subsequent amplification.
Primers for the polymerase chain reaction (PCR) were de-
signed to flank at least one putative intron site for rat TGF-131,
alpha 2 type IV collagen, and 13-actin. For TGF-131, the sense
primer corresponded to base pairs 1142-1168 and the antisense
primer to base pair 1520-1546 [17]. The two primers were
constructed to cross intron #5 and #6. For alpha 2 type IV
collagen, the sense primer corresponded to base pairs 55 62-5584
and the antisense primer to base pair 6100-6123, as described by
Peten et al [18]. For f3-actin, the sense primer corresponded to
base pairs 331-354 and the antisense primer to base pair 550-571
[19]. The two primers were constructed to cross intron #2. The
primer sequences were as follows:
5' CGA GGT GAC CTG GGC ACC ATC CAT GAC
3' CTG CTC CAC CTT GGG CTT GCG ACC CAC
5' ACT CAT TCC AAC CGT CTG TCA GC
3' GCA AAT CAT TGA CAG TGG CGT CTA
5' AAC CCT AAG GCC AAC CGT GAA AAG
3' TCA TGA GGT AGT CTG TCA GGT
The expected PCR product size for the TGF-131 primers was 405
base pairs, for the 13-actin primers, 240 base pairs, and for the a 2
type IV collagen, 562 base pairs. For amplication, 5 pA of the RT
product were combined with 6.5 pA of PCR mix containing 0.1 /M
of each of the primer pairs. Two units of Taq polymerase were
then added. Coamplification of f3-actin was performed to stan-
dardize the amount of RNA subjected to reverse transcription for
each time point. The sample was placed onto a Perkin Elmer
DNA Thermal Cycler (Model 480) and heated to 94°C for four
minutes, followed by 30 temperature cycles. Each cycle consisted
of three periods: (1) denature, 94°C for three minutes; (2)
cool-anneal, 60°C for three minutes; (3) heat-extend, 72°C for
three minutes. When the number of temperature cycles was
increased to 34, there was an increase in both the 405 bp and 240
bp PCR product with the above conditions. Serial dilutions (1:2
and 1:4) of the RT products were also subjected to PCR ampli-
cation for 30 temperature cycles for the normal and two-week
untreated diabetic samples. After amplification, the PCR prod-
ucts were separated by electrophoresis on a 1.0% agarose gel
containing ethidium bromide, photographed, and transferred to a
nylon membrane (Hybond N).
An antisense oligonucleotide, synthesized to serve as amplifi-
cation product-specific probe for TGF-131, spanned base pairs
1394-1424 (5' GOT GTA CTG TGT GTC CAG GTC CAG GCT
CCA AAT GTA 3'), respectively. A second antisense oligonucle-
otide was synthesized to serve as amplification product-specific
probes for 13-actin and spanned base pairs 427—456 (5' CAC AAT
GCC AGT GGT ACG ACC AGA GGC ATA 3'), respectively. A
third antisense oligonucleotide was synthesized to serve as ampli-
cation product-specific probes for the a 2 chain of type IV
collagen and spanned base pairs 5781—5804 (5' CCT GCA GTC
TTC CTA AAA TGA GGC 3'), respectively [18]. By design, each
oligonucleotide localized to a sequence that was inside the
amplification primer sequences. The oligonucleotides was labeled
with 32P-ATP (4500 Ci/mmol) utilizing T4 DNA kinase. The nylon
Rat TGF-f31
Mouse a 2
Type IV collagen
Rat /3-actin
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filters were hybridized overnight at 55°C, washed and exposed to
X-ray film at room temperature with an intensying screen for 30
to 120 minutes. The autoradiograms were quantitated with a GS
300 Transmittance/Reflectance Scanning Densitometer (Hoefer
Scientific Instruments) utilizing a MacIntosh Classic II (System
7.0) and Dynamax HPLC Method Manager (V1.2).
Immunohistochemisty
Following brietal anesthesia (50 mg/kg), the kidneys were
removed and the capsule excised. Blocks of renal cortical tissue
were immersed in OCr, and snap frozen in liquid nitrogen.
Cryostat sections (5 m) were mounted on poly-L-lysine coated
slides. Immunoperoxidase staining was performed by the ABC
method. Sections were fixed in acetone (4°C), air dried, then
quenched in methanol containing 3% H202 at room temperature
for 20 minutes. The sections were washed for five minutes in tap
water followed by a 15 minute incubation in pepsin to activate
antigenic sites. The sections were incubated at room temperature
overnight with specific TGF-f31 antiserum (R&D Systems, Min-
neapolis, Minnesota, USA) and diluted 1:100 in antibody diluting
buffer (Dimension Laboratories Ltd., Missisauga, Ontario, Cana-
da). After a PBS wash, sections were incubated at room temper-
ature for 30 minutes with an antirabbit IgG biotinylated antibody
(Vectastain Elite Kit, Vector Lab, Burlingame, California, USA),
diluted 1:200 with PBS. Finally, sections were washed and then
incubated for 30 minutes with an avidin-biotin-peroxidase com-
plex (diluted 1:50 in PBS). The sites of peroxidase activity were
visualized by incubation in DAB solution (Zymed Lab, California,
USA) for two minutes. Sections were counterstained with Harris
modified hematoxylin with acetic acid (Fisher Scientific) for 45
seconds, washed, cleaned, and covered with a glass cover slip.
Negative control experiments were performed by either (1)
replacing the primary antibody with antibody diluting buffer, or
(2) replacing the primary antibody with nonimmune rabbit anti-
serum (1:4000).
Semiquantitative assessment of immunohistochemical staining for
TGF-131
The immunostaining was scored by examining each glomerular
profile (range 18 to 27 profiles) in cryostat sections from three
normal and three untreated diabetic rats. Each profile was
assigned a score from 0 to 4, where 0 is no staining, 1 minimal
(25% of the glomerular tuft), 2 mild (50% of the glomerular tuft),
3 moderate (75% of the glomerular tuft), and 4 marked (100% of
the glomerular tuft). A score was derived for each animal:
4
Score Fi(i)
i= 1
4
where Fi is the percentage of glomeruli in the rat with a given
score i [20J.
Mean glomerular volume
Glomerular tuft volume (VG) was determined by measuring
the mean glomerular cross-sectional area (AG) of all glomerular
profiles in the cryostat sections. A 100 point grid was superim-
Table 1. Values for blood glucose in normal rats (NC), untreated
diabetic rats (D-), and insulin-treated diabetic rats (DI-)
Group
Blood glucose
mmol/liter
NC 4.7 0.1
D- 24 hr 18.4 1.7
D- 48 hr 16.8 1.4
D- 96 hr 17.6 1.9
D- 1 week > 22.0
D- 2 week > 22.0
DI- 24 hr 16.0 1.4
DI- 48 hr 10.6 1.1
DI- 72 hr 7.8 0.8
DI- 96 hr 2.9 0.5
DI- 1 week 4.7 0.3
DI- 2 week 5.4 0.8
Values are means SE.
posed over each glomerular profile. Each point represented 625
j2 and the number of points overlying each profile was enumer-
ated. Mean glomerular volume was calculated from AG by the
method of Weibel:
VG = x (AG)3 x ()
where 3 = 1.38 is the shape coefficient for spheres (the idealized
shape of glomeruli) and k = 1.1 is a size distribution coefficient
L211.
Analysis
The statistical significance of differences among values of
individual parameters was assessed with an unpaired Student's
t-test. Significance was defined as P < 0.05.
Results
Animal model
Streptozotocin was administered to rats weighing an average of
276 6 g. Over the course of the experiment, diabetic rats lost
weight so that by two weeks, the mean body weight was 235 10
g. Average blood glucose levels for normal rats (NC), untreated
diabetic rats (D), and the insulin-treated diabetic rats (DI) during
the course of the study are shown in Table 1. In accord with the
experimental design, blood glucose levels remained above 15
mmol/liter in the diabetic rats, exceeding 22 mmol/liter two weeks
after the administration of streptozotocin. Despite the decrease in
body weight that accompanied early untreated hyperglycemia,
there was an absolute increase in kidney weight compared to
age-matched normal rats. As illustrated in Figure 1, whole kidney
weight averaged 1.60 0.07 g after two weeks of hyperglycemia
compared to 1.31 0.06 g in the normal rats (P < 0.05). The ratio
of kidney weight to body weight was almost twofold greater in the
diabetic rats compared to the normal rats (0.69 0.03% vs. 0.46
0.02%, P < 0.05). As expected, there was a significant increase
in glomerular volume in the diabetic rats compared to the age-
matched normal rats, with mean values averaging 0.97 0.16 106
j.t in normal rats and 1.97 0.12 106 in diabetic rats (P < 0.05)
(Fig. 2). Intensive insulin treatment served to normalize blood
glucose levels in streptozotocin-induced diabetic rats (Table 1).
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Fig. 2. Glomerular volume (VG) in normal rats (NC) and untreated
diabetic rats 2 weeks after the onset of hyperglycemia (D- 2 week). VG was
significantly greater in untreated diabetic rats than in age matched normal
rats. Values are mean 1 SE. *p < 0.05.
RT-PCR
The effect of hyperglycemia on steady state levels of TGF-f31
mRNA relative to steady state levels of mRNA for /3-actin was
determined by coamplication RT-PCR in glomerular and renal
cortical samples (Figs. 3 and 4). Figure 3 shows the autoradio-
graphs that were used for densitometry. Individual values for the
ratio of the densitometry measures of the PCR products for
TGF-131 and /3-actin in diabetic rats 24, 48, 96 hours, one week
and two weeks after the onset of hyperglycemia, in normal rats,
and insulin-treated diabetic rats are listed in Table 2.
In glomerular samples from normal rats, the ratio of the
densitometry measures of the PCR products for TGF-/31 and
/3-actin was 0.39 (Fig. 4). A similar ratio was obtained from a
separate group of five normal rats. Twenty-four hours after the
onset of hyperglycemia there was a 1.75-fold increase in the ratio
of the densitometry measures of the PCR products for glomerular
TGF-j31 and /3-actin so that by 96 hours there was a 2.5-fold
increase. The increased ratio of the densitometry measures of the
PCR products for TGF-/31 and /3-actin was sustained one and two
weeks after the onset of hyperglycemia in glomeruli. Intensive
insulin treatment reversed the trend observed in untreated dia-
betic rats, and the ratio of the densitometry measures of the PCR
products for TGF-/31 and /3-actin approached normal values after
two weeks. The relative changes in mRNA levels were also
observed when serial dilutions of the RT products from normal
and two-week untreated diabetic rats were subjected to PCR
amplication for 30 temperature cycles.
In renal cortical samples from normal rats, the ratio of the
densitometry measures of the PCR products for TGF-f31 and
/3-actin was 0.61 (Fig. 4). A similar ratio, 0.58, was obtained in a
separate group of five normal rats. The change in the ratio of the
densitometry measures of the PCR products for TGF-/31 and
j3-actin was delayed in renal cortical tissue compared to glomeruli.
Twenty-four hours after the onset of hyperglycemia there was only
a 1.25-fold increase in the the ratio of the densitometry measures
of the PCR products for renal cortical TGF-pl and /3-actin. By 96
hours there was a 2.0-fold increase the ratio of the densitometry
measures of the PCR products for TGF-J31 and /3-actin. The ratio
continued to increase so that one week after the onset of
hyperglycemia there was a 3.0-fold increase in the ratio of the
densitometry measures of the PCR products for TGF-/31 and
/3-actin. Like the measures obtained for glomeruli, the increase in
the ratio was sustained two weeks after the onset of hyperglycemia
in renal cortical tissue. Intensive insulin treatment initiated after
the onset of hyperglycemia reversed the trend observed in the
untreated diabetic rats, and the ratio of the densitometry mea-
sures of the PCR products for TGF-f31 and /3-actin approached
normal values after two weeks.
A comparison was made between the densitometry measures of
the PCR products for TGF-/31 and /3-actin from euglycemic rats
and hyperglycemic rats. Values from normal rats (NC) and
euglycemic diabetic rats (DI) were grouped (N = 4) and com-
pared to values from the hyperglycemic untreated diabetic rats
(D) (N = 5). For glomerular samples, there was a significant
increase in the ratio of the densitometry measures of the PCR
products for TGF-/31 and /3-actin in hyperglycemic diabetic rats
compared to the euglycemic rats (0.87 0.08 vs. 0.57 0.08, P <
0.05). For renal cortical samples, there was also a significant
increase in the ratio of the densitometry measures of the PCR
products for TGF-/31 and /3-actin in hyperglycemic diabetic rats
compared to the euglycemic rats (0.67 0.05 vs. 1.30 0.18, P <
0.05). These results are illustrated in Figure 5.
The effect of hyperglycemia on steady state levels of a 2 type IV
collagen mRNA relative to steady state levels of mRNA for
/3-actin was determined by coamplication RT-PCR in glomeruli of
normal rats (N = 3) and untreated diabetic rats (N = 3) one week
after the onset of hyperglycemia (Fig. 6). In samples from normal
rats, the ratio of the densitometry measures of the PCR products
for a 2 type IV collagen and 13-actin was 1:40. One week after the
onset of hyperglycemia there was a 1.3-fold increase in the ratio of
the densitometry measures of the PCR products for a 2 type IV
collagen and /3-actin in glomeruli from diabetic rats compared to
glomeruli from normal rats.
D
2 weeks
2.0
1.5
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Fig. 1. Kidney weight in normal rats (NC) and untreated diabetic rats 2
weeks after the onset of hyperglycemia (D- 2 week). Kidney weight was
significantly greater in untreated diabetic rats than in age matched normal
rats. Values are mean I SE. *P < 0.05.
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Fig. 3. Autoradiographs of the coamplifi cation of TGF-f31 and 13-actin mRNA in glomeruli (A) and renal cortical tissue (B) from normal rats (C), untreated
diabetic rats (D-) and insulin treated diabetic rats (DI-).
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Fig. 4. Ratios of the densitometiy readings for the RT-PCR amplification of
TGF-131 and 3-actin mRbJA in glomendi (closed bars) and renal cortical
tissue (hatched bars) from normal rats (NC) and untreated diabetic rats (D-).
Immunohistochemistty
The effect of hyperglycemia on immunostaining for TGF-/31 in
the renal cortex of the kidney is illustrated in the five panels of
Figure 7. Panels A and D show the appearance of kidney tissue
from both normal or diabetic rats when the primary antibody is
omitted from the protocol or replaced with non-immune serum.
In the absence of specific antiserum there is no immunoperoxi-
dase staining of glomeruli (Panel A) or renal tubules (Panel D).
Panel B shows typical glomerular immunostaining for TGF-/31 in
Table 2. Ratios of the densitometiy readings for the RT-PCR
amplification products of TGF-/31 and 13-actin in normal rats (NC),
untreated diabetic rats (D-), and insulin-treated diabetic rats (DI-)
Time Renal cortex Glomeruli
NC 0.61 0.39
D- 24 hr 0.86 0.71
D- 48 hr 0.90 0.67
D- 96 hr 1.37 1.07
D- 1 week 1.75 0.97
D- 2 week 1.65 0.94
NC 0.58 0.39
DI-1 week 0.78 0.68
DI-2 week 0.73 0.66
a normal rat. In this glomerulus, the immunostaining is more
prominent at the vascular pole of the glomerulus. Panel C shows
typical glomerular immunostaining for TGF-f31 in a diabetic rat
two weeks after the onset of hyperglycemia. Marked glomerular
immunostaining is present in the glomerular capillary tuft. Panel
E shows typical tubular immunostaining for TGF-pl in cortical
tubules of normal rats. The immunostaining pattern was faint and
segmental. Panel F shows the increased segmental immunostain-
ing for TGF-131 that was evident in cortical tubules of diabetic rats
two weeks after the onset of hyperglycemia.
Semiquantitative scoring of glomerular immunostaining for
TGF-f31 in normal and diabetic rats yielded values of 1.67 0.06
(N = 3) and 3.25 0.30 (N = 3), respectively, so that there was
a twofold increase in immunostaining for TGF-f31 during the early
phase of diabetic glomerular hypertrophy (Fig. 8).
Discussion
The mechanisms that lead to renal injury in patients with type
I diabetes mellitus remain poorly understood. Early investigators
Hours
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showed that the glomerular filtration rate was greater than normal
in young adults with diabetes mellitus [221, while further studies
established that the increase in glomerular filtration rate was
accompanied by an increase in kidney size and glomerular volume
[231. The subsequent observation that enlarged, hyperfiltering
kidneys of diabetic patients ultimately fail suggests that mecha-
nisms responsible for maintaining early increases in glomerular
filtration rate and kidney size may be important in the pathogen-
esis of renal injury [24].
More recently, studies by Yoshida, Fogo and Ichikawa [251 of
rats with renal ablation have led to the suggestion that an increase
in glomerular size is an important determinant of glomerular
injury. Glomerular growth in experimental diabetes mellitus is
characterized predominantly by structural hypertrophy, as auto-
radiographic studies have shown that there is no cellular prolif-
eration in the glomerulus [26, 27]. Early glomerular hypertrophy
is accompanied by an increase in peripheral capillary wall surface
area that parallels the rise in glomerular filtration rate [3]. Later,
glomeruli develop localized and/or diffuse expansion of the me-
sangial matrix, leading to a reduction in glomerular filtration rate
[3]. Thus, it is tempting to speculate that changes in gene
transcription accompanying diabetes-induced glomerular hyper-
trophy are important in the development of glomerular injury.
Accordingly, the objective of the current study was to examine
changes in mRNA levels and protein expression during the phase
of rapid glomerular hypertrophy that follows the onset of hyper-
glycemia.
A number of polypeptide growth factors regulate growth and
extracellular matrix production but many recent studies have
focused on transforming growth factor (TGF-131). In vitro,
TGF-131 is expressed by proximal tubule cells and glomerular
endothelial, epithelial and mesangial cells [7, 9, 11, 28]. TGF-pl
has been implicated in the pathogenesis of mesangial expansion in
experimental glomerulonephritis [10, 29], and Wolf et al have
reported that exposure to a high glucose concentration doubles
levels of mRNA for TGF-/31 in cultured mesangial cells [4].
Therefore, the first major aim of the current study was to test the
hypothesis that steady state levels of mRNA for TGF-131 increase
in glomeruli during the phase of rapid glomerular hypertrophy of
diabetic rats that follows the onset of hyperglycemia.
Our major finding is that TGF-/31 expression increases during
the phase of rapid renal hypertrophy in both the glomeruli and
renal tubules of rats with experimental type I diabetes mellitus.
Two weeks after the onset of hyperglycemia, when renal hyper-
trophy is established but before glomerulosclerosis develops,
there is a demonstrable increase in immunostaining for TGF-131
in both the glomeruli and renal cortical tubules. In contrast,
MacKay and coworkers found that mRNA levels for TGF-j31
decreased in glomeruli of rats one to two weeks after uninephrec-
tomy [30]. It is tempting to speculate that a sustained increase in
TGF-pl expression may play a role in diabetic glomerular injury.
Moreover, taken together, these observations suggest that glomer-
ular hypertrophy per se may not be a determinant of injury. The
pattern of gene expression accompanying glomerular hypertrophy
may be more important.
The RT-PCR analysis further showed that TGF-f31 expression
rose more rapidly in glomeruli than in renal cortical tissue. Steady
state levels for TGF-f31 mRNA increased approximately twofold
24 hours after the onset of hyperglycemia in glomeruli, while a
comparable increase occurred only after 96 hours in renal cortical
tissue. This time course corresponds to the phase of rapid
glomerular hypertrophy [31]. Rasch and Norgaard have studied
3H-thymidine uptake in glomeruli and renal cortical tissue of
diabetic rats during this period [261. No uptake was demonstrated
in glomeruli, but there was an early increase in 3H-thymidine
uptake in cortical tubules, indicating some cellular hyperplasia.
3H-thymidine uptake returned to baseline four days after the
onset of hyperglycemia.
TGF-/31 has a wide spectrum of cellular effects, and one of the
most prominent is inhibition of cell proliferation [32, 33]. Our
observations suggest that TGF-f31 may modulate the cellular
growth response to hyperglycemia in vivo because an early
increase in glomerular TGF-f31 expression could function in an
autocrine and/or paracrine fashion to prevent cell division. Recent
studies by Choi et al support this hypothesis [13]. TGF-j31 directly
inhibited mesangial cell proliferation and increased cell size in
vitro [13]. Moreover, when mesangial cells are exposed to high
glucose concentrations, the cells proliferate, but a subsequent rise
in TGF-pl production inhibits proliferation [4, 28]. Neutralizing
antibody to TGF-f31 sustains the proliferative response, indicating
that TGF-f31 functions in an autocrine fashion to inhibit cell
division. These studies suggest that the early increase in TGF-J31
in diabetic glomeruli may play a similar role in vivo. Similar effects
have been shown in vitro with proximal tubule cells [5], so that the
early tubular cell hyperplasia in the renal cortex, observed by
Rasch and Norgaard may be attenuated by the subsequent rise in
TGF-pl expression.
The mechanism(s) by which TGF-f31 controls the cell cycle has
been actively studied. The TGF-j31 receptor is a serine/threonine
kinase [34—38], and growth inhibition by TGF-131 have been
linked to the phosphorylation status of the retinoblastoma gene
product (RB protein) [39]. TGF-j31 arrests cells in Gi by reducing
the phosphoiylation of RB protein [40]. This post-translational
modification of RB protein prevents the cell from entering the S
phase of the cell cycle [26, 39]. In addition, TGF-pl may also
change the phosphorylation state of P53 [41], as well as reduce the
level of c-myc protein [42], effects that prevent cell proliferation.
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Fig. 5. Ratios of the densitometty readings for the RT-PCR amplification of
TGF-131 and -actin mRNA from euglycemic rats (closed bars) (N = 4) and
hyperglycemic rats (hatched bars) (N = 5) in glomeruli (G) and renal cortical
tissue (RC). Values are mean 1 SE. *D < 0.05 vs. euglycemic rats.
G RC
— 562 bp
— 240 bp
— Collagen
— -actin
C iweek
C 1 week
436 Shankland and Scholey: TGF-(31 during hyperirophy
Fig. 6. A. UV transilluminated photograph of the
PCR products for a 2 lype IV collagen (562 bp)
and 13-actin (240 bp) in normal rats (C),
and untreated diabetic rats, one week
(D- I week) after the onset of hyperglycemia.
B. Autoradiographs of the coamplification of a
2 type IV collagen and /3-actin mRNA in
normal (C) and untreated diabetic glomeruli
(D- 1 week).
Previous studies have shown that mRNA levels for TGF-f31 do that immunostaining for TGF-p1 would increase in glomeruli and
not always correlate with protein levels [301. Therefore, the renal cortical tissue along with the changes in mRNA levels during
second major aim of the current study was to test the hypothesis the phase of rapid glomerular hypertrophy that follows the onset
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Fig. 7. Photomicrographs of TGF-/31 immunoreactivity in nonnal and diabetic rat kidney tissue. A. There is no immunostaining in glomeruli when the
primary antibody is ommitted from the protocol or replaced by non-immune rabbit serum. B. Typical glomerular immunostaining for TGF-/31 in a
normal rat. C. Typical glomerular immunostaining for TGF-f31 in an untreated diabetic rat two weeks alter the onset of hyperglycemia. D. There is no
immunostaining in tubules when the primary antibody is ommitted from the protocol or replaced by non-immune rabbit serum. E. Typical segmental
tubular immunostaining for TGF-f31 in a normal rat. F. Typical segmental tubular immunostaining for TGF-J31 in an untreated diabetic rat two weeks
after the onset of hyperglycemia (mag — 530X).
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Fig. 7. Continued.
of hyperglycemia. Two weeks after the onset of hyperglycemia, TGF-!31 immunostaining in both glomeruli and renal cortical
when there was an approximately twofold increase in TGF-j31 tissue, demonstrating that changes in TGF-131 mRNA levels were
mRNA levels, we found that there was a marked increase in associated with a change in protein expression.
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Fig. 7. Continued.
Steffes, Brown and Basgen have shown that islet cell transplan- suggest that renal growth and factors that lead to mesangial
tation normalizes blood glucose levels and reduces mesangial expansion in diabetic glomeruli are at least partially reversible.
expansion in diabetic rats [43]. Taken together, these studies Accordingly, the third aim of the current study was to test the
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hypothesis that normalization of blood glucose levels by intensive
insulin treatment would prevent the rise in mRNA for TGF-/31 in
glomeruli. Importantly, intensive insulin treatment to normalize
blood glucose levels attenuated the changes in TGF-f31 mRNA.
Moreover, the results of these studies showed that changes in
TGF-131 expression were not due to a non-specific effect of
streptozotocin.
Our results are consistent with the hypothesis that there may
also be a link between early changes in gene expression during
glomerular hypertrophy and subsequent glomerular injury. One
week after the onset of hyperglycemia co-amplification RT-PCR
showed a modest 1.3-fold increase in glomerular mRNA levels for
a 2 type IV collagen compared to -actin. Fukui et al have shown
that mRNA levels for a 1 type IV collagen also increase in the
glomeruli of diabetic rats, although Northern blot analysis was
performed four weeks after the onset of hyperglycemia [44]. Ihm
et al examined a 1 type IV collagen mRNA levels in the glomeruli
of diabetic rats one week after the onset of hyperglycemia and
were unable to detect any increase in glomerular mRNA levels for
a 1 type IV collagen by either slot-blot hybridization or in situ
hybridization [45]. There was no difference between the glomer-
ular volumes of control and diabetic rats seven or 28 days after
administration of streptozotocin in this study, which may account,
in part, for the modest increase in a 2 type IV collagen mRNA
that we observed in the current study.
It is tempting to speculate that an early rise in TGF-f31
expression in the diabetic glomeruli may be responsible for an
increase in a 2 type IV collagen mRNA levels. TGF-131 has been
shown to modulate extracellular matrix production by cells in vitro
[6, 32, 33, 46—481, and extracellular matrix proteins accumulated
in the mesangium and basement membrane of diabetic glomeruli
[49—52]. In vitro, glomerular mesangial and epithelial cells [53, 54]
both increase synthesis of extracellular matrix proteins including
proteoglycans, decorin, fibronectin, type IV collagen and laminin
in response to TGF-f31 [46, 54—56]. Moreover, TGF-/31 inhibits
production of collagenases [57, 58], and increases production of
tissue inhibitors of metalloproteinases (TIMP) [59]. Both of these
effects could lead to a decrease in extracellular matrix protein
degradation, thus contributing to the accumulation of matrix
proteins in the diabetic glomerulus [44, 45, 49—52, 60—63].
Studies by Border and coworkers have directly implicated
TGF-131 in the pathogenesis of extracellular matrix protein accu-
mulation in experimental glomerulonephritis because neutralizing
antibodies to TGF-131 attenuate glomerular injury [10, 29, 64], and
a recent report by Nakamura and coworkers [54] indicates that
mRNA levels for TGF-131 remain elevated in glomeruli up to 24
weeks after the onset of hyperglycemia [10]. Yamamoto et al have
also reported that TGF-31 immunostaining is increased in the
glomeruli of diabetic rats and the glomeruli of patients with
clinical diabetes mellitus [14]. In the rats with experimental
diabetes mellitus the increase in TGF-J31 correlated with increases
in expression of the extracellular matrix proteins fibronectin and
biglycan. Taken together, these studies suggest that an early and
sustained increase in TGF-131 expression in diabetic glomeruli
may be responsible for the development of diabetic glomerulopa-
thy.
In summary, the current study establishes that there is an
increase in TGF-f31 mRNA levels and protein expression in
glomeruli and renal cortical tissue during the phase of rapid renal
hypertrophy that follows the onset of hyperglycemia in streptozo-
tocin-induced diabetic rats. Normalization of blood glucose levels
with insulin treatment attenuates the rise in TGF-pl mRNA
levels. These studies suggest that changes in gene expression
during glomerular hypertrophy may link injury and structural
hypertrophy.
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